Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...

June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, ...

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. The deal, ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal ...

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 ...

Travere Therapeutics ( (TVTX)) has shared an update. On May 11, 2026, Travere Therapeutics completed a registered underwritten public offering of $525 million aggregate principal amount of 0.50% ...

Travere Therapeutics Inc, a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease, announced ...

SAN DIEGO, May 12, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity ...